ロード中...
Multiple Source Biosimilar Insulin, What’s a Provider to Do?
In the United States the FDA designates generic products that are bioequivalent as AB substitutable (FDA rating signifying the approved application contains adequate scientific evidence establishing through in vivo and/or in vitro studies the bioequivalence of the product to a selected reference pro...
保存先:
| 出版年: | J Diabetes Sci Technol |
|---|---|
| 第一著者: | |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
SAGE Publications
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4454116/ https://ncbi.nlm.nih.gov/pubmed/24876532 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1932296813511748 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|